RESEARCH PAPER
Cognitive impairment among HIV-infected adults on antiretroviral therapy in Indonesia
1
Department of Internal Medicine, Medical Faculty, Hasanuddin University, Makassar 90245, Indonesia
2
Department of Psychiatry, Medical Faculty, Hasanuddin University, Makassar 90245, Indonesia
3
Department of Biostatistics, Public Health Faculty, Hasanuddin University, Makassar 90245, Indonesia
Submission date: 2021-04-17
Final revision date: 2021-06-08
Acceptance date: 2021-06-09
Publication date: 2023-01-24
HIV & AIDS Review 2023;22(1):38-42
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Human immunodeficiency virus (HIV) infection and its related complications remain a health problem in developing countries. Cognitive impairment is a complication of HIV infection and is often undetected. Untreated cognitive impairment can lead to decreased quality of life. This study aimed to determine the prevalence of cognitive impairment among HIV-infected patients and its associated risk factors.
Material and methods:
A cross-sectional study was conducted at Wahidin Sudirohusodo Hospital Makassar Indonesia, from October to December 2020. It involved 93 HIV outpatients aged 18-59 years. Cognitive impairment was determined by the Montreal cognitive assessment (MoCA) test. Blood samples were taken for CD4, anti-HCV, and routine blood tests. Nadir (lowest ever) CD4 and antiretroviral therapy (ART) information were obtained from patient medical records. Data were analysed using SPSS version 22. The statistical tests used were the chi-square test and multiple logistic regression.
Results:
Cognitive impairment was found in 47.3% of subjects. Bivariate analysis found a significant relationship between age 41-59 years (p = 0.025), nadir CD4 count < 200 cells/μl (p = 0.001), and anaemia (p = 0.04) with cognitive impairment. Multivariate analysis showed that the most significant factors associated with cognitive impairment were nadir CD4 count < 200 cells/μl (OR 4.4; 95% CI: 1.75-11.17) and age 41-59 years (OR 3.0; 95% CI: 1.01-8.73).
Conclusions:
The prevalence of cognitive impairment was found to be high in HIV-infected adults receiving ART. Low nadir CD4 count (40 years old) was identified as a risk factor associated with impaired cognitive function.
Human immunodeficiency virus (HIV) infection and its related complications remain a health problem in developing countries. Cognitive impairment is a complication of HIV infection and is often undetected. Untreated cognitive impairment can lead to decreased quality of life. This study aimed to determine the prevalence of cognitive impairment among HIV-infected patients and its associated risk factors.
Material and methods:
A cross-sectional study was conducted at Wahidin Sudirohusodo Hospital Makassar Indonesia, from October to December 2020. It involved 93 HIV outpatients aged 18-59 years. Cognitive impairment was determined by the Montreal cognitive assessment (MoCA) test. Blood samples were taken for CD4, anti-HCV, and routine blood tests. Nadir (lowest ever) CD4 and antiretroviral therapy (ART) information were obtained from patient medical records. Data were analysed using SPSS version 22. The statistical tests used were the chi-square test and multiple logistic regression.
Results:
Cognitive impairment was found in 47.3% of subjects. Bivariate analysis found a significant relationship between age 41-59 years (p = 0.025), nadir CD4 count < 200 cells/μl (p = 0.001), and anaemia (p = 0.04) with cognitive impairment. Multivariate analysis showed that the most significant factors associated with cognitive impairment were nadir CD4 count < 200 cells/μl (OR 4.4; 95% CI: 1.75-11.17) and age 41-59 years (OR 3.0; 95% CI: 1.01-8.73).
Conclusions:
The prevalence of cognitive impairment was found to be high in HIV-infected adults receiving ART. Low nadir CD4 count (40 years old) was identified as a risk factor associated with impaired cognitive function.
REFERENCES (31)
1.
Alford K, Vera JH. Cognitive impairment in people living with HIV in the ART era: a review. Br Med Bull 2018; 127: 55-68.
2.
Clifford DB, Ances BM. HIV-associated neurocognitive disorder. Lancet Infect Dis 2013; 13: 976-986.
3.
Cross S, Önen N, Gase A, Overton ET, Ances BM. Identifying risk factors for HIV-associated neurocognitive disorders using the international HIV dementia scale. J Neuroimmune Pharmacol 2013; 8: 1114-1122.
4.
Mukherjee T, Sakthivel R, Fong HY, et al. Utility of using the Montreal Cognitive Assessment (MoCA) as a screening tool for HIV-associated neurocognitive disorders (HAND) in multi-ethnic Malaysia. AIDS Behav 2018; 22: 3226-3233.
5.
de Souza EM, Buoniconti CS, Valim FC, Moura AS. Risk factors for neurocognitive impairment in HIV-infected patients and comparison of different screening tools. Dement Neuropsychol 2016; 10: 42-46.
6.
Ku NS, Lee Y, Ahn JY, et al. HIV-associated neurocognitive disorder in HIV-infected Koreans: the Korean NeuroAIDS Project. HIV Med 2014; 15: 470-477.
7.
Zhang Y, Qiao L, Ding W, et al. An initial screening for HIV-associated neurocognitive disorders of HIV-1 infected patients in China. J Neurovirol 2012; 18: 120-126.
8.
Olivier IS, Cacabelos R, Naidoo V. Risk factors and pathogenesis of HIV-associated neurocognitive disorder: The role of host genetics. Int J Mol Sci 2018; 19: 3594. doi: 10.3390/ijms19113594.
9.
Yideg Yitbarek G, Mossie Ayana A, Bariso Gare M, Garedew Woldeamanuel G. Prevalence of cognitive impairment and its predictors among HIV/AIDS patients on antiretroviral therapy in Jimma University Medical Center, Southwest Ethiopia. Psychiatry J 2019; 2019: 8306823. doi: 10.1155/2019/8306823.
10.
Heaton RK, Franklin DR, Ellis RJ, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol 2011; 17: 3-16.
11.
Wright EJ, Grund B, Robertson K, et al. Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons. Neurology 2010; 75: 864-873.
12.
Ciccarelli N, Fabbiani M, Grima P, et al. Comparison of cognitive performance in HIV or HCV mono-infected and HIV-HCV co-infected patients. Infection 2013; 41: 1103-1109.
13.
Smurzynski M, Wu K, Letendre S, et al. Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort. AIDS 2011; 25: 357-365.
14.
Ciccarelli N, Fabbiani M, Di Giambenedetto S, et al. Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients. Neurology 2011; 76: 1403-1409.
15.
Hasbun R, Eraso J, Ramireddy S, et al. Utility of the Montreal Cognitive Assessment Test. J AIDS Clin Res 2012; 3: 186. doi: 10.4172/2155-6113.1000186.
16.
Joska JA, Witten J, Thomas KG, et al. A comparison of five brief screening tools for HIV-associated neurocognitive disorders in the USA and South Africa. AIDS Behav 2016; 20: 1621-1631.
17.
Estiasari R, Imran J, Lastri DN, Prawiroharjo P, Price P. Cognitive impairment among Indonesia HIV naïve patients. Neurol Asia 2015; 20: 155-160.
18.
Estiasari R, Aryanto I, Lee S, Pramana S, Djauzi S, Price P. Determinants of cognitive health in Indonesian HIV patients beginning antiretroviral therapy. J Neurovirol 2020; 26: 32-40.
19.
Letendre SL, Ellis RJ, Ances BM, McCutchan JA. Neurologic complications of HIV disease and their treatment. Top HIV Med 2010; 18: 45-55.
20.
Cross HM, Combrinck MI, Joska JA. HIV-associated neurocognitive disorders: antiretroviral regimen, central nervous system penetration effectiveness, and cognitive outcomes. South African Med J 2013; 103: 758-762.
21.
Chan LG, Kandiah N, Chua A. HIV-associated neurocognitive disorders (HAND) in a South Asian population – contextual application of the 2007 criteria. BMJ Open 2012; 2: e000662. doi: 10.1136/bmjopen-2011-000662.
22.
Aung HL, Bloch M, Vincent T, et al. Cognitive ageing is premature among a community sample of optimally treated people living with HIV. HIV Med 2021; 22: 151-164.
23.
Robertson KR, Smurzynski M, Parsons TD, et al. The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS 2007; 21: 1915-1921.
24.
Saylor D, Dickens AM, Sacktor N, et al. HIV-associated neurocognitive disorder – pathogenesis and prospects for treatment. Nat Rev Neurol 2016; 12: 234-248.
25.
Kallianpur AR, Wang Q, Jia P, et al. Anemia and red blood cell indices predict HIV-associated neurocognitive impairment in the highly active antiretroviral therapy era. J Infect Dis 2016; 213: 1065-1073.
26.
Gattas BS, Ibetoh CN, Stratulat E, et al. The impact of low hemoglobin levels on cognitive brain functions. Cureus 2020; 12: e11378. doi: 10.7759/cureus.11378.
27.
Hinkin CH, Castellon SA, Levine AJ, Barclay TR, Singer EJ. Neurocognition in individuals co-infected with HIV and hepatitis C. J Addict Dis 2008; 27: 11-17.
28.
de Almeida SM, de Pereira AP, Pedroso MLA, et al. Neurocognitive impairment with hepatitis C and HIV co-infection in Southern Brazil. J Neurovirol 2018; 24: 339-349.
29.
Kahouadji Y, Dumurgier J, Sellier P, et al. Cognitive function after several years of antiretroviral therapy with stable central nervous system penetration score. HIV Med 2013; 14: 311-315.
30.
Ma Q, Vaida F, Wong J, Sanders CA, et al. Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients. J Neurovirol 2016; 22: 170-178.
31.
Lopardo GD, Bissio E, Iannella MDC, Crespo AD, Garone DB, Cassetti LI. Good neurocognitive performance measured by the international HIV dementia scale in early HIV-1 infection. J Acquir Immune Defic Syndr 2009; 52: 488-492.
Share
RELATED ARTICLE
| eISSN: | 1732-2707 |
| ISSN: | 1730-1270 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
